<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047605</url>
  </required_header>
  <id_info>
    <org_study_id>173 S 09 PSY</org_study_id>
    <secondary_id>2009-015827-97</secondary_id>
    <nct_id>NCT01047605</nct_id>
  </id_info>
  <brief_title>Pharmacological Effects of Neurapas® Balance and Pascoflair® 425 mg on Brain Activity in Healthy Volunteers</brief_title>
  <acronym>NCAG 5209</acronym>
  <official_title>Evaluation of the Pharmacological Effects of NEURAPAS® Balance and PASCOFLAIR® 425 mg by Quantitative Measurement of Brain Activity in 16 Healthy Volunteers. A Single-blinded, Randomised, Placebo-controlled, 3-armed Phase-I-study With Cross-over Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pascoe Pharmazeutische Praeparate GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pascoe Pharmazeutische Praeparate GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacological effects of two herbal medicinal products (Neurapas balance&#xD;
      and Pascoflair 425 mg) in comparison to placebo on brain activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the pharmacological effects of Neurapas® balance and Pascoflair® 425 mg by&#xD;
      quantitative measurement of brain activity in 16 healthy volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Z1: qEEG (total): Median change of electrical activity (qEEG: of all electrode positions) compared to Baseline (PP1 vs PP2 vs Placebo)</measure>
    <time_frame>5 times within 4 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison PP1 vs PP2 vs Placebo: Z2: qEEG (all frequencies, Clusters): Median change of electrical activity (qEEG: of selective brain-regional clusters of electrode positions) compared to Baseline</measure>
    <time_frame>5 times within 4 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison PP1 vs PP2 vs Placebo: Z3:qEEG (d2, beta1 (Cluster F7/T3))</measure>
    <time_frame>5 times wihtin 4 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison PP1 vs PP2 vs Placebo: Z4:qEEG (ME, theta (Cluster F7/T3/T6))</measure>
    <time_frame>5 times within 4 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison PP1 vs PP2 vs Placebo: Z5:qEEG (KLT, theta (Cluster F7/T3) + alpha (Cluster T4/T6))</measure>
    <time_frame>5 times within 4 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison PP1 vs PP2 vs Placebo: Z6: qEEG (Aa, all frequencies, Cluster C3/T3/P4)</measure>
    <time_frame>5 times within 4 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison PP1 vs PP2 vs Placebo: Z7: Timely onset of effect and duration of effect</measure>
    <time_frame>5 times within 4 h</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PP1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neurapas balance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PP2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pascoflair 425 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PL1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>P-Tabletten weiß</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neurapas balance</intervention_name>
    <description>6 tablets single dose</description>
    <arm_group_label>PP1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pascoflair 425 mg</intervention_name>
    <description>3 tablets , single dose</description>
    <arm_group_label>PP2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P-Tabletten weiß</intervention_name>
    <description>3 tablets, single dose</description>
    <arm_group_label>PL1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female volunteers&#xD;
&#xD;
          -  30 - 70 years (extremes included)&#xD;
&#xD;
          -  Medical history without any study relevant pathological findings&#xD;
&#xD;
          -  Written and signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically study relevant acute or chronic disorders, that can be detected by clinical&#xD;
             investigation or medical history&#xD;
&#xD;
          -  Clinical, study-relevant pathological findings of clinical oar laboratory&#xD;
             investigations&#xD;
&#xD;
          -  Clinically relevant pathological EEG findings (e.g. artefact-free parts in&#xD;
             Screening-EEG &lt;30% in one recording&#xD;
&#xD;
          -  Clinically relevant allergies&#xD;
&#xD;
          -  positive alcohol testing on Screening, Day A, B, or C, or anamnestic&#xD;
&#xD;
          -  positive drug screening test on Screening, Day A, B, or C, or anamnestic&#xD;
&#xD;
          -  Intake of study relevant medication 14 days prior to active Day A, or during active&#xD;
             study duration, based on the volunteer´s information&#xD;
&#xD;
          -  Regular intake of drug with primary central nervous effects (e.g. psychoactive drugs&#xD;
             or central acting antihypertensive drugs)&#xD;
&#xD;
          -  Known hypersensitivity / allergy against herbal extracts (i.e. dry extracts of&#xD;
             Passionflower herb, St. John´s Wort herb, Valerian root) or lactose or an other&#xD;
             excipient of the investigational medication&#xD;
&#xD;
          -  Lapp-lactase deficiency (anamnestic)&#xD;
&#xD;
          -  Hypersensitivity of the skin (anamnestic)&#xD;
&#xD;
          -  BMI (Body-Mass-Index) &lt;18 or&gt;30&#xD;
&#xD;
          -  Abuse of caffeine, teeine, or tobacco&#xD;
&#xD;
          -  Smoking in the investigational site on Day A, B, or C&#xD;
&#xD;
          -  Participation in an other clinical study within 60 days prior to Screening&#xD;
&#xD;
          -  Positive Pregnancy Test (on Screening, Day A, B, or C) or Lactation&#xD;
&#xD;
          -  Bad compliance&#xD;
&#xD;
          -  Revocation of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winfried Wedekind, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurocoed AG, Sportparkstr. 9, D-35578 Wetzlar, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wilfried Dimpfel, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Neurocode AG, Sportparkstr. 9, D-35578 Wetzlar, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anja Braschoss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pascoe Pharmazeutische Praeparate GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurocode AG</name>
      <address>
        <city>Wetzlar</city>
        <zip>D-35578</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <last_update_submitted>May 14, 2010</last_update_submitted>
  <last_update_submitted_qc>May 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Anja Braschoss, MD</name_title>
    <organization>PASCOE pharmazeutische Praeparate GmbH</organization>
  </responsible_party>
  <keyword>qEEG</keyword>
  <keyword>herbal medicine</keyword>
  <keyword>cognitive function</keyword>
  <keyword>Neurapas balance</keyword>
  <keyword>Pascoflair</keyword>
  <keyword>hypericum</keyword>
  <keyword>passionflower</keyword>
  <keyword>valerian</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Influence on quantitative electro-encephalogram (qEEG).</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

